Repetitive sequences are hotspots of evolution at multiple levels. However, due to technical difficulties involved in their assembly and analysis, the role of repeats in tumor evolution is poorly understood. We developed a rigorous motif-based methodology to quantify variations in the repeat content of proteomes and genomes, directly from proteomic and genomic raw sequence data, and applied it to analyze a wide range of tumors and normal tissues. We identify high similarity between the repeat-instability in tumors and their patient-matched normal tissues, but also tumor-specific signatures, both in protein expression and in the genome, that strongly correlate with cancer progression and robustly predict the tumorigenic state. In a patient, the hierarchy of genomic repeat instability signatures accurately reconstructs tumor evolution, with primary tumors differentiated from metastases. We find an inverse relationship between repeat-instability and point mutation load, within and across patients, and independently of other somatic aberrations. Thus, repeat-instability is a distinct, transient and compensatory adaptive mechanism in tumor evolution.
Introduction
Cancer clonal evolution (Cairns, 1975; Nowell, 1976 ) is marked by a wide range of genomic instabilities and somatic aberrations which lead to intratumor heterogeneity and eventually enable tumor cells to proliferate and metastasize (Stratton et potential role as disease drivers in somatic evolution (Persi et al., 2016) .
In light of the importance of repeats in rapid evolutionary processes, coupled with their demonstrated involvement in human pathology, we hypothesized that repeat dynamics might play a more important role in tumor evolution than presently realized, especially, given that, in tumors, repeat generation is likely to be enhanced due to impaired DNA replication (Loeb et al., 1974; Tomasetti et al., 2017 ) and repair (Duval & Hamelin, 2002) . To test this hypothesis, we generalized the quantification of repetitive motifs beyond microsatellites, and developed a rigorous methodology to systematically quantify variations in the repeat content (repeat-instability) of genomes (bypassing difficulties associated with assembly) and in the expression of repeat-containing proteins, directly from genomic and proteomic sequence raw data.
We applied the developed methodology to a collection of diverse datasets (Table 1) , including (i) a proteomic dataset of breast cancer patients, (ii) genomic datasets of prostate cancer patients, including an original cohort of benign tissues, serving as a non-cancerous control, (iii) genomic pan-cancer cohorts from The Cancer Genome Atlas (TCGA) which include a tumor sample, an adjacent matched-normal control and a blood sample from each individual, providing for a comparison between tissues, and (iv) samples from patients with metastatic spread which allowed analysis of repeat-instability during the evolution from the primary tumor to the metastatic state. We demonstrate the utility of the methodology for identifying tissue-specific and tumor-specific repeat-instability signatures in cancer and normal tissues, and elucidate the dynamics and role of repeat-instability in tumor evolution.
Results

Measuring repeat-instability in amino-acid and nucleotide sequences
To measure the repetitiveness of motifs (k-mers) in a set of sequences, we define the compositional order ratio (CR) of a motif, as the total number of the motif recurrences divided by the total number of sequences in which the given motif appears (Figure 1a and Methods). The CR is high when a motif recurs multiple times in a sequence. Sequences in which motifs are highly recurrent are regarded as compositionally ordered. The CR signal tested on the human proteome strongly departs from the random expectation (Figure 1b) , and furthermore, CR is substantially more robust for repeat identification than alternative measures of repetitiveness, such as the frequency of a motif or its fraction in the proteome ( Figure S1 ).
The CR can be directly estimated from both proteomic and genomic raw data (Figure 1a) . In proteomic data, CR is evaluated from a list of ~100K measured peptides (typically 10-30 amino-acids long) and their abundances; the abundance values are used to estimate the effective number of sequences. We used triplets (k=3, 8000 amino-acid triplets) to measure CR in proteomic data, which is the optimal choice of motif length to characterize protein repeats (Persi & Horn, 2013) . In whole exome sequencing (WES) data (coverage depth 100X), CR is computed from a list of ~100-200M short DNA reads (typically, 50-150 base-pairs long), using hexamers (k=6, 4096 nucleotide hexamers), such that the proteomic and genomic motif spaces have comparable sizes. The choice of k=6, a shorter unit length than the naïve choice of k=9 which translates into an amino-acid triplet, is also justified by the occurrence of synonymous substitutions that do not change the amino-acid composition (Methods). For CR evaluation, motifs can overlap and do not need to recur in tandem, such that all types of repeats, both pure and diverged, from runs to repetitive domains, that are shorter than half of the short-read length, can be identified (Methods). Several examples of repeats in proteins and their respective coding nucleotide repeats, identified in our analysis, are shown below, emphasizing the diversity of repeats that can be captured. Analysis of genomic data demonstrates that CR is a stable measure, which saturates at a low coverage depth ( Figure S2 ) and is unbiased with respect to the sample size ( Figure S3) .
We define the repeat-instability signature (RIS=∆CR) of a sample as the sum of the CR percentage changes for all motifs compared to a control sample (Methods). In a patient, the somatic signature of a tumor is computed relative to a control sample, taken either from an adjacent matched-normal tissue or from the blood. genomic data. Because repeats can expand or contract in a given genome, we evaluate the overall repeat-instability by the sum over the absolute value of the signatures of all motifs (ORI=∑|∆CR|).
Importantly, proteomic signatures reflect the compound effect of somatic genome instability and 6 differential expression of repeat-containing peptides, whereas genomic signatures reflect genome instability alone. We applied this methodology to analyze peptide sequences in the proteomic dataset and short-read nucleotide sequences in the genomic (WES) datasets (Table 1) .
Proteomic repeat-instability reflects breast cancer tumor progression
We first applied the repeat analysis methodology to the proteomic dataset from 21 breast cancer patients (Pozniak et al., 2016 ) (Methods and Table1). We found that the CR of motifs (amino-acid triplets) tends to increase in tumors relative to matched-normal tissues, as measured by the average signature of triplets across patients (Figure 2a) . To ensure that this trend was not a consequence of large variations of CR in a few patients, we assessed the frequency of variation in the CR among the patients. The histogram of the frequencies is bimodal, with CR consistently increasing for many triplets and consistently decreasing for a few triplets among the patients (Figure 2b) . The remarkable shift to high frequency that was observed for strongly altered (>1%) triplets confirms that CRincrease is the dominant phenomenon and CR can be used to characterize tumors. Principal component analysis (PCA) of the CR estimates (52 samples x 1229 triplets) shows clear separation of matched-normal samples from tumor samples in the first 2 principal components (Figure 2c ). This separation was captured in two experimental pools (Table 1 and Methods), indicating that the tumor vs normal segregation is robust. The PCA analysis also suggests that the dimensionality of discrimination is low, such that classifiers can be built using a small number of discriminative features (i.e., triplets). Examples of discriminative triplets (e.g., PVP, APV, APA, YGY, DVL, TAA) are shown in Figure S4 .
To further test the predictive signal of repeat-instability signatures, we built binary classifiers that discriminate between normal and tumor samples, using support vector machine (SVM) with a linear kernel, and examined various feature-selection criteria in a standard leave-one-out analysis (Methods ,   Table S1 ). Every tested selection criterion (Kolmogorov-Smirnov test, Fisher-score and CR-based criteria) achieved classification accuracy >80% with a small set of triplets (~10-30). We further inspected the simplest criterion for selecting triplets with high CR, i.e. those that frequently recur in the list of identified peptides. This approach achieved a maximum accuracy of 89% with only 36 selected triplets (Table S1) that are frequently and significantly altered among the patients ( Figure   S4 ). To ensure that the classifier performance is not sensitive to the small number of samples, we also tested its performance as a function of the number of samples, and found that it improves as more samples are included, testifying to the generality and robustness of this simple approach for discriminating between tumor and normal samples (Figure 2d ).
Although good performance was achieved in discriminating tumor from normal samples, metastases do not appear to be well separated from primary tumors (Figure 2c) . Nonetheless, we noticed that several triplets displayed consistent variation from normal to primary tumor to metastases (e.g., the triplet TAA in Figure S4) . Thus, to test for signatures correlated with cancer progression, we selected triplets with the strongest average signature in the metastases (relative to matched-normal), and tested whether their signatures varied from stage II to stage III. This particular comparison was performed because selection of triplets with strong signatures in the metastases statistically selects weaker signatures in stages II and III, but differences between stage II and stage III are not expected to be affected ( Figure S5) . As implied by the tendency of CR-increase in tumors, we found more triplets with average signatures increased from stage II to stage III (Figure 2e ) than triplets for which the average signatures decreased (Figure 2f) . These trends were robust to the choice of the threshold used to select triplets with strong signatures in metastases ( Figure S5 ). Notably, a weaker variation between stage III and metastases was observed, suggesting that the differential expression of repeats is especially important at early stages of tumor evolution. Mapping all discriminative triplets to proteins and identifying repeat-unstable proteins (Methods) indicated that the proteins with high repeat-instability are enriched among the proteins encoded by known cancer genes ( Figure S6 ) which is compatible with a role of repeat instability in oncogenesis.
The proteomic CR signatures reflect changes in expression levels of repeat-containing proteins and, accordingly, do not directly convey any information on genomic somatic variation in the repeat content in protein-coding DNA. Hence, to explore the role of repeat-instability in somatic evolution, we turn to the analysis of genomic data. Hereafter, we analyze short reads of nucleotide sequences obtained from WES data ( Table 1) .
Genomic repeat-instability discriminates between healthy and cancerous prostate tissues
We explored genomic repeat-instability in prostates, the tissue type with the richest dataset among the ones examined, which includes samples from both healthy individuals and cancer patients (Table1).
We analyzed the TCGA dataset of prostate cancer patients (Cancer Genome Atlas Research Network, 2015), focusing on cases for which a primary tumor sample and two control samples, from blood and from an adjacent matched-normal tissue, were collected. In each patient (n=41), we computed the CR signatures of the tumor and of the adjacent normal samples relative to blood. In most of the patients, the signatures of tumor and adjacent normal samples were closely similar, displaying strong positive correlation (Figure 3a and Figure S7 ). This correlation was independent of the shape of the signatures (i.e., expansion-dominated or contraction-dominated), implying that the signatures are primarily tissue-specific ( Figure S7) . Furthermore, high similarity between tumors and normal samples is also observed across patients, as demonstrated by the bimodal distribution of the pairwise correlations ( Figure S7) , which reflects the prevalence of positive or negative correlation between the signatures from different patients, a consequence of the dominance of either repeat expansion or contraction, in a given genome.
To determine whether these repeat-instability signatures include tumor-specific characteristics, we compared them to signatures of benign prostate hyperplasia (BPH) from healthy individuals not affected by prostate cancer (n=15, here referred to as healthy individuals) that were computed relative to matched blood ( Table 1) . Superposition of tumor and benign signatures (Figure 3a, left panel) highlights strong similarity between prostate cancer and healthy tissues but the healthy signatures are weaker. This difference is recapitulated by the overall repeat-instability (ORI=∑|ΔCR|), which shows high similarity between tumor and adjacent normal tissues in cancer patients, but a lower instability of the benign prostates in healthy individuals (Figure 3a, right panel) . However, these differences had limited statistical significance, emphasizing the strong tissue specificity of the signatures. Thus, to identify tumor-specific features, we trained SVM classifiers as in the proteomic case but, to account for the expansion-dominated and contraction-dominated genomic signatures; we considered the absolute value (|ΔCR|) in our analysis. Tumor tissues were robustly discriminated from benign ones ( Table 2 , task 1), and 154 discriminative motifs were identified using Kolmogorov-Smirnov test (Pvalue < 0.001): 133 showed flat signatures and 21 exhibited strong contraction in benign tissues relative to tumors. The classifiers cannot distinguish between tumor and adjacent normal signatures when each is computed relative to blood, and no discriminative motifs were found ( Table 2 , task 2), as expected from their close similarity. Using adjacent normal tissues as a control in place of blood leads to significantly weaker signatures (Figure 3a) . Nonetheless, these signatures contain tumorspecific information as the identified discriminative motifs between these signatures and those of benign tissues largely overlap those that were identified in task 1 ( Table 2 , task 3). Therefore, this comparison yields an attenuated tumor signature. We used this signature when a blood sample was missing.
To test the predictive power of the 154 discriminative motifs, we considered an independent dataset (Barbieri et al., 2012) of 111 prostate cancer patients ( Table 1) . The repeat-instabilities of the test and training sets showed remarkable similarity (Figure 3b) . The similarity between tumor and adjacent matched-normal signatures, but not with healthy signatures, implies that the adjacent normal prostate tissues in cancer patients contain tumor-specific features, in the absence of histological evidence. We validated this prediction using various training-test sets, demonstrating that tumors are predicted with high accuracy (>90%), based on both tumor and adjacent normal signatures ( Figure S8 ).
To explore which genes were most affected by repeat-instability, we mapped the short reads encompassing repeats from the Barbieri dataset onto the human genome, and estimated repeatinstability at the gene level (Methods). We found that the 10 most unstable motifs, with |∆CR|>5% in >80% of the patients (Figures 3a), were not discriminative and did not map to coding regions, but rather to regulatory regions ( Figure S9 ). Because these dominant signatures appear in all tissues, including benign prostates, it seems likely that they represent repeat hotspots in non-coding regulatory regions that might exert currently unknown effects on transcription regulation (Vinces et al., 2009 ). In contrast, discriminative motifs mapped to protein-coding regions ( Figure S9 ). As in the proteomic case, the set of most repeat-unstable genes was significantly enriched in known cancer genes ( Figure S10 ). We analyzed in detail the amino-acid and nucleotide compositions of the identified repeat-unstable genes. This analysis also emphasized the ability of our methodology to identify diverse types of repeats (Methods), from runs of amino-acids in proteins, as exemplified by the glutamine tracks in FOXP2 protein ( Figure S11) , to repetitive domains, as in the case of the Cysteine-rich PAK1 inhibitor CRIPAK (Figure S12) , based on the recurrence of hexamers in the protein-coding DNA.
Lastly, we explored the relationship between repeat-instability and other somatic aberrations by querying the Barbieri dataset. The overall repeat-instability of discriminative motifs was weakly inversely related to the non-silent point mutation load, but was independent of copy-number alterations (i.e., DNA burden) and aneuploidy status (Figure 3c ). The apparent, even if weak, tradeoff between repeat-instability and the mutation load suggests that, in tumor evolution, repeatinstability could be a compensatory mechanism for point mutations. To test this hypothesis, we performed a pan-cancer analysis, exploring a wider distribution of mutation loads.
Genomic repeat-instability is inversely related to somatic point mutation load in the pan-cancer dataset
In addition to the prostate adenocarcinoma analyzed above, 3 additional cancer types were selected from TCGA ( Table 1 Across cancer types, we identified a consistent inverse relationship between the overall repeatinstability and the number of non-silent point mutations, which was independent of the overall genomic burden (Figure 4a ). Despite the similarity between adjacent normal and tumor signatures observed in each patient (Figure S13), patients with low mutational load cancers (i.e., breast) display higher repeat-instability in normal tissues when compared to the respective tumor signatures, whereas for high mutational load cancers (bladder and lung), this trend is reversed. In prostate patients, the similarity between tumors and the normal tissues was the highest, explaining the difficulty in identifying tumor-specific features in this case, and the need for a non-cancerous control (cf. Figure   3 ). Thus, repeat instability is high when the mutation load is low and low when the mutation load is high, and this effect is stronger for the signatures of adjacent normal tissues in the vicinity of tumors than for the tumor signatures themselves. The inverse relationship between the point mutation load and the overall repeat instability holds both for gain (expansion) and loss (contraction) of repeats, but is more pronounced for gain ( Figure S14) .
Further, to elucidate the differences between cancer and adjacent normal genomes across tissues, we 
Genomic repeat-instability recapitulates tumor phylogeny within patients and correlates with metastatic spread
To substantiate the role of repeat-instability as a distinct and compensatory mutation class in tumor evolution, we studied two patients with metastatic spread ( Table 1 in particular, to the untreated primary tumor (despite marked difference in the overall repeatinstability between these samples), as previously inferred using independent techniques (Faltas et al., 2016) and, (iii) metastases from the same anatomical site cluster together, with few differences. The finding that the repeat-instability approximated phylogenies are closely similar to the true phylogenies suggests that repeat-instability evolves by divergence, at clock-like rates.
To test the hypothesis that repeat-instability is a compensatory adaptive path of tumor evolution, we compared the overall repeat-instability and the non-silent point mutation load in primary tumors and metastatic sites. In both patients, repeat-instability was higher in primary tumors than in metastases, corroborating the inverse relationship between repeat-instability and the point mutation load ( Figure   5 , right panels). These findings imply that repeat-instability is most pronounced at early stages of tumor progression, likely, acting as a transient genome alteration that compensates for the relatively low number of driver mutations in primary tumors, and is partially reversed as mutations accumulate and tumor cells adapt.
Discussion
The involvement of repeat-instability in human pathology is supported by ample evidence (Wooster . However, the current understanding of the role of this phenomenon in somatic evolution is mostly limited to microsatellites. In this study, we describe a method that measures the repeat content in the genome and in the proteome, directly from proteomic peptide data and genomic short-reads.
Our approach accounts for a wide range of repeats. Applying this approach to an array of studies allowed us to assess repeat-instability across many patients and in different tissue types, comparing tumors with normal tissues, yielding insights into its role in tumor evolution.
Our analyses of genomic signatures show that, compared to blood, cancer and adjacent normal tissues , it is substantially diverged from other tissues, and is therefore an adequate choice as an outgroup control for characterizing repeat-instability (and other somatic aberrations). Also, the effective population size of blood cells is likely large, so that purifying selection is highly efficient. Therefore, blood is likely to be largely free of deleterious mutations, and hence, an adequate control. Conversely, the relatively low rates of cell divisions in bladder and lung tissues likely contribute to the overall lower repeat-instability in these tissues.
Collectively, these observations indicate that repeat-instability is a distinct adaptive path in tumor evolution. We propose a model of tumor evolution (Figure 6a) in which, at the initial phase of tumorigenesis (low mutational load cancers at the pan-cancer level, and primary tumors at the patient level), the number of cancer driver mutations is low, and repeat-instability is likely to serve as an additional, complementary mechanism, which increases (or maintains) the fitness of tumors. Later in tumor evolution, when metastases and/or high mutation load tumors accumulate more mutations and subsequently more drivers, repeat-instability is reduced as tumors adapt to their specific ecological According to our model, at the initial phase of tumor evolution, repeat-instability can compensate for the lack of sufficient number of cancer drivers and thus increase the tumor fitness, whereas later in evolution, high repeat-instability negatively affects tumor fitness and is selected against. A positive correlation between high microsatellite instability with better prognosis in cancer patients has been reported (Hause et al., 2016). In the context of our model, these findings are likely to reflect stages of tumor progression at which repeat-instability already exceeded the optimal value. The existence of compensatory adaptive paths, that is, point mutations vs. repeat-instability, suggests that, although the dynamic range of somatic aberrations in cancers is substantial, the fitness of tumors tends to be more stable over time and can be robust to environmental pressure. (Figure 6b ). These parallels with findings on species evolution should inform the study of repeat instability in somatic evolution of cancer.
Further integrated genomic-proteomic research is needed to study how somatic changes in the genomic DNA are translated into differential expression of repeat-containing peptides and how new copies diverge by accumulating mutations during tumor evolution. Such research could lead to the identification of new cancer drivers and the development of therapeutic strategies, in particular immunotherapies, which target this mutational class. Furthermore, given that our results indicate that repeat-instability is an adaptive mechanism that is important at the early stages of tumor evolution, we hypothesize that repeat instability signatures may be relevant for early cancer detection by cellfree DNA and liquid biopsy analysis as well as other methods. The role of repeat instability in other pathologies and evolutionary scenarios has yet to be explored.
Methods
Measuring Repeat Instability in Genomes and Proteomes
The extent of repetitiveness of a motif m, in a genome or proteome, is measured by its compositional order ratio (CR), as illustrated in Figure 1A , defined as the number of the motif recurrences in a set of sequences divided by the number of sequences in which it appears: The existence of compositionally ordered sequences in a proteome is responsible for the fact that some motifs will tend to recur multiple times in a relatively small number of sequences, and will therefore have high CR. For proteomic data, we use amino-acid triplets (k=3, N m =8000) which is the optimal motif length for characterizing protein repeats (Persi & Horn, 2013) . The significance of CR evaluation is demonstrated in Figure S1 , where we compare the SwissProt human reference proteome to random models (with identical length distribution of proteins), and compared CR with other measures such as the frequency of motifs or their fraction in the proteome (i.e., the number of sequences in which motifs appear).
The variation in the repetitiveness of a motif m between two samples, in particular, between a tumor tissue and its matched-normal tissue or a blood sample, is measured in percentages by:
where CR 1 m and CR 2 m are the CR of motif m in samples 1 and 2, respectively. The repeat-instability signature is then expressed as the spectrum of ΔCR of all motifs, and the overall repeat-instability is given by the sum over the absolute values of motifs' variations, ∑ m |∆CR m |.
To find an adequate motif length (i.e., k) for the analysis of genomic data, we first performed a systematic search of all DNA k-mers (with 3 ≤ k ≤ 9) on few patients. Variations in CR of motifs in DNA were not evident at k=3, whereas for large k (k>6), the vocabulary size is too large to allow a useful analysis. Hence, working with a motif vocabulary size comparable to that used in proteomic data, choosing k=6, such that N m =4096, was sufficient for the identification and characterization of repeat content at the DNA level. The choice of k=6 represents a shorter unit length than the naïve choice of k=9, which translates into an amino-acid triplet. As nucleotide nonamers can harbor many synonymous substitutions that do not change the amino-acid composition, even a tandem array composed of exact copies of amino-acid triplets is not expected to be coded by exact copies of nucleotide nonamers. The lengths of recurring motifs at the DNA level are thus expected to be shorter than 9. Conversely, repetitive hexamers in the protein-coding DNA may identify repeats that are not observed in protein sequences, due to insertions and deletions.
To validate that the identification of repetitive hexamers in nucleotide sequences significantly overlap the repeats in proteins (identified by repetitive triplets) we analyzed the repeat content of all human proteins. We employed the compositional order methodology (Persi & Horn, 2013) to both the amino-acid sequences using triplets and to the corresponding protein-coding DNA using hexamers. In random sequences, the probability of identifying a motif that recurs more than n time in a sequence of length L is determined by the Bernoulli distribution: ( , ; ≥ ) = ∑ ( ) (1 − )
, where p is the probability of selecting a k-mer over an alphabet A, such that p=1/A k (i.e., 1/8000 for amino-acids and 1/4096 for nucleotides). Hence, for a given k and A, n can be set to ensure a comparable statistical significance of identifying a recurrent element. By this consideration, we searched the human proteome for amino-acid triplets that recur at least 5 times in a protein, and nucleotide hexamers that recur at least 8 times in the respective protein-coding DNA. This analysis largely identified the same (~5000) repeat-containing proteins (Jaccard score 0.6). Hence, although there are obvious differences between the results of searching for repetitive triplets in amino-acid sequences and searching for repetitive hexamers in corresponding nucleotide sequences, basing the large-scale analysis in this study on k=3 and k=6, respectively, appears as a reasonable choice.
Evaluation of the number of motif recurrences in sequences allows overlap, such that all types of repeats can be identified. For example, in the sequence AAAAAAAAA, the hexamer AAAAAA recurs 4 times, capturing runs of nucleotides. Consequently, in genomic data, runs of nucleotides shorter than 6 bp are discarded. Similarly, in the sequence ATATATATATA the dinucleotide tandem repeats are captured by the hexamers ATATAT and TATATA, each recurring 3 times. Because motifs need not recur in tandem and all short motifs over the alphabet are evaluated, all types of repeats are considered when evaluating CR, including highly diverged repeats and long motifs. Note that many short motifs (i.e., triplets and hexamers) will recur in sequences composed of longer repeats, and hence, long repeats are also captured. Obviously, the longest motif that can be identified is limited by half the short read length. For further details on how the developed procedure captures all types of repeats, from runs of amino-acids to long repetitive domains, in protein sequences, see (Persi & Horn, 2013) . Examples of protein repeats and their corresponding coding DNA repeats, in repeat unstable genes identified in this study, are provided in Figures S11-S12.
Importantly, other genomic aberrations, such as segmental duplication and gene copy-number alterations, can alter CR if they encompass compositionally ordered regions (in which motifs are recurrent within the short-read length). Therefore, CR should be interpreted as a global measure of the repeat content that weighs in the contribution of other somatic aberrations that involve repeatcontaining proteins. However, in this study, we have found that repeat-instability was independent of copy-number alterations or of ploidy (cf. Figures 3 and 5) . Hence, in practice, CR is weakly sensitive to such changes in the analyzed datasets.
Application of CR Analysis to Proteomic Datasets
Proteomic data of tumor samples and their matched-normal samples were obtained from 21 breast cancer patients ( Table 1) 
Application of CR Analysis to Genomic Datasets
To analyze the genomic datasets ( Table 1) , CR evaluation was applied directly to Fasta-q files of each sample, generated from BAM files using Samtool and Bedtool. In all datasets, the length of the DNA short reads was 76 base-pairs. We assumed no prior knowledge of the directionality such that the entire raw data, including unmapped reads, was considered for CR evaluation. In each short-read, a nucleotide that had a probability of error P err > 0.05, as specified by its Phred-score, was labeled as 'N'. Then, a search for valid DNA k-mers (i.e., k-mers that do not contain N) was performed. The effective number of invalid short-reads in a sample, E, that is, the number of base-pairs with P err > 5% divided by 76, the short-read length, was of the order of 5-10% in these datasets. The length of short reads sets an upper bound on the possible number of recurrences within a short-read, and in turn on CR. Hence, for comparison across studies, it is essential that the short read length of NGS is identical. Further, we found that different sequencing kits affect CR evaluation. Thus, we performed all our analysis based on samples that where sequenced with the same kit (SureSelect).
In all datasets, coverage depth was approximately x50-100. With such large coverage depth, CR is highly stable, as demonstrated by its saturation at very low coverage depths, and the fast convergence of the statistical errors of CR to a narrow distribution, as more and more data (i.e., short-reads) is considered for CR evaluation ( Figure S2 ). These statistical errors may arise due to various effects, such as unequal sampling of genomic regions. Nonetheless, empirical estimation of the statistical error of CR shows that it is relatively small (mean and median ~ 10 -4 ), and consequently, by propagation of errors, the statistical error of the repeat instability signature (ΔCR) is also of the order 10 -4 (that is, 0.01%). Note that a somatic change in the DNA (e.g., an expansion of a motif) will be sampled proportionally to the coverage depth and will therefore be identified, over the background of the statistical fluctuations.
Benign Prostate Hyperplasia Dataset
After informed consent, benign prostatic hyperplasia (BPH) tissue samples were collected from patients who underwent surgical resection due to symptomatic BPH. Samples were examined and annotated by expert genitourinary pathologists. Tissue cores were taken for DNA extraction followed by whole exome or whole genome sequencing (>40X 
Mapping Motifs to Genes and Estimating Repeat-Instability in Genes
To map motifs to genes, we extracted from the raw data those sequences in which motifs are highly recurrent (≥2 in peptides, ≥4 in DNA short reads), and mapped them to the human genome/proteome.
Evaluation of CR for genes is not practical because, unlike motifs, only a small fraction of the reads map to a given gene, resulting in significant noise in the estimates of CR at the gene level. In genomic data, we mapped all compositionally ordered sequences to the human genome using BWA, assigning to each read the most likely gene to which it belongs. Then, for each gene, we estimated the total weighted recurrence in each sample as: A = Σ h WR h , where R h is the total number of recurrences of hexamer h in all the mapped sequences, and W = 1/(N sr -E) is a constant weight factor of the relative abundance of short-reads in a sample: N sr is the total number of short-reads in the entire sample, and E is the number of invalid short-reads, such that A is comparable between two samples of different size and across patients. The mapping of two sets of hexamers, the 154 discriminative hexamers and dominant hexamers (cf. Table 2 and Figure 3 ) is shown in Figure S9 .
Then, we assessed ∆A for all genes containing discriminative hexamers. Genes that were identified as repeat-unstable in at least 75% of the patients in the Barbieri dataset (n=3321) were considered for enrichment analysis with known cancer genes ( Figure S10) .
In proteomic data, mapping triplets is straightforward because the vast majority of triplets occur in only one or a few peptides, and each peptide is maps uniquely to one protein. This mapping is provided by the output of MaxQuant which compares the similarity of peptides to proteins in the UniProt database. A is weighted by the measured abundance intensities of each peptide, such that A = Σ t W t R t , where W t is the intensity of the peptides matched to a gene in which the triplet t recurs R t times. Two maps for each experimental pool (described above) were built (for a set of discriminative triplets). We considered a valid mapping (triplets to peptides to genes) only if in both experimental pools a given triplet recurred in identical peptides (and thus genes). We mapped the discriminative triplets identified by Fisher-score and Kolmogorov-Smirnov tests, by CR-based criteria, or by their 20 association with cancer progression (Figure 2 , and Table S1 ). For enrichment analysis, we selected those triplets that have consistent variation across patients (i.e., CR-increase in >70% of the patients or CR-decrease in >70% of the patients, as in Figure 3B ). These triplets mapped to 491 proteins which are enriched with 63 known cancer genes ( Figure S6 ).
Statistical and Machine Learning Tools
Principal component analysis (PCA) was applied to the matrix of CR evaluations, of patients (observations) x motifs (features). The CR matrix was standardized such that each column is normalized by its standard deviation across observations. Support vector machine (SVM) with linear
Kernel function was used for the classification tasks in a standard leave-one out procedure. Because they lack mutations, repeat instability is even larger than that of the corresponding tumors (that already have adapted), but is also quickly reduced as the transition to a neoplastic state is not achieved and normal cellular function is retained. Later in evolution (i.e., metastases and high ML cancer types), the number of driver mutations increases, tumors are more adapted and repeat instability reduces. At least in high mutation load cancers, the accumulation of passenger mutations (P) outcompete the drivers (P>D); hence, cancers resort to purifying selection (S<0), which reduces the repeat-instability. Hence, repeat-instability acts as a transient, compensatory mechanism. The faster transient effect in adjacent normal tissues explains their higher repeatinstability in low mutation load cancers and their lower repeat-instability in high mutation load cancers, relative to the respective tumors. B) Repeats content, measured as the vocabulary of amino-acid triplets that compose protein repeats, correlates with ordering of organisms by the product of effective population size and mutation rate (adapted from [Persi & Horn, 2013] ). Tables   Table 1: Figure S9 for the predictive signal of the discriminative hexamers.
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